



HAL
open science

Cost- effectiveness of a simplified acute malnutrition program: a secondary analysis of the OptiMA randomized clinical trial in the Democratic Republic of the Congo

Stephen C Resch, Ryoko Sato, Kevin Phelan, Cecile Cazes, Abdramane Ombotimbe, Victoire Hubert, Harouna Boubacar, Lievin Izie Bozama, Gilbert Tshibangu Sakubu, Beatrice Kalenga Tshiala, et al.

► To cite this version:

Stephen C Resch, Ryoko Sato, Kevin Phelan, Cecile Cazes, Abdramane Ombotimbe, et al.. Cost-effectiveness of a simplified acute malnutrition program: a secondary analysis of the OptiMA randomized clinical trial in the Democratic Republic of the Congo. *Health Policy and Planning*, 2024, 10.1093/heapol/czae106 . hal-04844977

HAL Id: hal-04844977

<https://hal.science/hal-04844977v1>

Submitted on 18 Dec 2024

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Cost- effectiveness of a simplified acute malnutrition program: a secondary analysis of the OptiMA randomized clinical trial in the Democratic Republic of the Congo

Corresponding Author: Stephen C. Resch; Harvard University TH Chan School of Public Health, Boston, 677 Huntington Avenue Boston, MA 02115. USA; sresch@hsph.harvard.edu

Authors:

Stephen C. Resch, PhD, Ryoko Sato, PhD, Kevin Phelan, MSc, Cécile Cazes, PhD, Abdramane Ombotimbe, MD, Victoire Hubert, MPH, Harouna Boubacar, BNurs, Liévin Izie Bozama, BAsC, Gilbert Tshibangu Sakubu, MD, Béatrice Kalenga Tshiala, BAsC, Toussaint Tusuku, MD, Rodrigue Alitanou, MD, Antoine Kouamé, BAsC, Cyrille Yao, MSc, Delphine Gabillard, PhD, Moumouni Kinda, MD, Renaud Becquet, PhD, Susan Shepherd, MD, Robert M. Hecht, PhD.

Affiliations

University of Bordeaux, National Institute for Health and Medical Research (INSERM) UMR 1219, Research Institute for Sustainable Development (IRD) EMR 271, Bordeaux Population Health Research Centre, Bordeaux, France (Cecile Cazes PhD, Delphine Gabillard PhD, Renaud Becquet PhD); The Alliance for International Medical Action (ALIMA), Paris, France (Kevin Phelan MSc.); ALIMA, Kamuesha, Democratic Republic of the Congo (Victoire Hubert MPH, Harouna Boubacar BNurs, Rodrigue Alitanou MD, Abdramane Ombotimbe MD); National Nutrition Programme, Ministry of Health, Kinshasa, Democratic Republic of the Congo (Liévin Izie Bozama BAsC, Béatrice Kalenga Tshiala BAsC, Toussaint Tusuku MD); Kamuesha Health Zone in the Kasai Province, Ministry of Health, Kamuesha, Democratic Republic of the Congo (Gilbert Tshibangu Sakubu MD); PACCI ANRS Research Programme, University Hospital of Treichville, Abidjan, Côte d'Ivoire (Antoine Kouamé BAsC, Cyrille Yao MSc); ALIMA, Dakar, Senegal (Moumouni Kinda MD, Susan Shepherd MD); Harvard University TH Chan School of Public Health, Boston, MA USA (Stephen C. Resch PhD, Ryoko Sato PhD), Yale University School of Public Health, New Haven, CT USA (Robert M. Hecht, PhD)

Contributors

	Conception of design of the work	Data collection	data analysis and interpretation	Drafting the article	Critical revision of the article	Final approval of the version to be submitted-
Stephen Resch	x		x	x	x	x
Ryoko Sato	x		x	x	x	x
Kevin Phelan	x				x	x
Cecile Cazes	x				x	x
Abdramane Ombotimbe		x				x
Victoire Hubert		x				x
Harouna Boubacar		x				x

The Author(s) 2024. Published by Oxford University Press in association with The London School of Hygiene and Tropical Medicine.

Lievin Izie Bozama		x				x
Gilbert Tshibangu Sakubu		x				x
Beatrice Kalenga Thiala		x				x
Toussaint Tusuku		x				x
Rodrigue Alitanou		x				x
Antoine Kouame		x				x
Cyrille Yao		x				x
Delphine Gabillard		x				x
Moumouni Kinda		x				x
Renaud Becquet	x				x	x
Susan Shepherd	x				x	x
Robert Hecht	x		x	x	x	x

SR, RH, RS, CC, RB, KP, SS developed the methodology for the economic analysis. SR, RS, and RH performed the economic analysis and all coauthors interpreted the results. AO oversaw the collection of cost data for the economic analysis. SS and RB developed the clinical and methodological study concept. RB, CC, DG, KP, and SS designed the clinical study methodology and wrote the protocol. CC, VH, HB, RA, and MK coordinated the clinical study teams. LIB, BKT, TT, and GTS coordinated the Ministry of Health of the Democratic Republic of the Congo staff working in the trial. CC, VH, HB, LIB, GTS, AK, CY, and RB organised and supervised data collection for the clinical trial. CY created the software tool for randomisation and developed the database. CC, DG, SS, and RB developed the statistical analysis strategy for the clinical study, CC performed the statistical analysis and all coauthors interpreted the results. SR wrote the first draft of the economic analysis manuscript with substantial inputs from RH, RS, KP, SS, and CC. SR, RH, RS, KP, and SS were primarily responsible for the final content of the manuscript. All authors critically reviewed the draft and made substantial writing contributions to the development of the final manuscript. All authors had full access to all the data in the study. SR, RS, and RH verified the underlying data of the study. SR, RH, RS, KP, and SS had final responsibility for the decision to submit the manuscript for publication.

Reflexivity statement: We have a wide range of authors in terms of demographic characteristics with various expertise. We have 6 females and 13 male coauthors. Some of us are medical doctors, others are economist, decision scientist, nutritionist, statistician, and epidemiologist. All authors have extensive experience conducting research in developing countries, especially in West Africa.

Keywords: Cost- effectiveness; acute malnutrition; randomized clinical trial; Democratic Republic of the Congo

Abbreviated running title: Cost-effectiveness analysis of nutrition program in DRC

Key messages

- To our knowledge, this is the first cost-effectiveness analysis of a randomized controlled trial of an integrated, simplified strategy of acute malnutrition treatment in children aged 6–59 months in the Democratic Republic of the Congo (DRC).
- We compared the cost and effectiveness of the current national standard strategy with that of the OptiMA strategy. The standard strategy has separate protocols and products for SAM and MAM management using RUTF at an increasing dose with increasing weight in children with SAM and ready-to-use supplementary food at a fixed dose in children with MAM. By contrast, the OptiMA strategy is a single protocol for both SAM and MAM using only RUTF at a decreasing dose with increasing weight.
- The cost-effectiveness analysis presented in this paper found that across all patients in the DRC trial with acute malnutrition, OptiMA was the dominant strategy (more effective at a lower cost) as compared to the national standard strategy.
- Adoption of the OptiMA approach would likely enable more children to be successfully treated at cost similar to that of the current status quo of separate and parallel SAM and MAM treatment programs prevailing in most countries of sub-Saharan Africa and other lower- and middle-income regions of the world.

Word count: 4072

Ethical approval

Ethical approval of the trial was granted by the Democratic Republic of the Congo National Ethics Committee (94/CNES/BN/PMMF/2018) and the Ethics Evaluation Committee of the French National Institute for Health and Medical Research (Approval number 18–545). Informed consent was obtained from the children’s caregivers.

Funding

The underlying study was primarily supported by the Innocent Foundation (London, UK, grant number ALIMA-2018-DRC) and received additional funding from the European Commission through the European Civil Protection and Humanitarian Aid Operations (ECHO, Brussels, Belgium, grant number ECHO/COD/BUD/2018/91023). The cost-effectiveness study was funded by the Innocent Foundation, USAID’s Bureau of Humanitarian Affairs, and Amade-Monaco. This Article covers humanitarian aid activities implemented with the financial assistance of the EU. The views expressed herein should not be taken, in any way, to reflect the official opinion of the EU, and the European Commission is not responsible for any use that might be made of the information it contains.

Acknowledgements

The study was primarily supported by the Innocent Foundation (London, UK, grant number ALIMA-2018-DRC) and received additional funding from the European Commission through the European Civil Protection and Humanitarian Aid Operations (ECHO, Brussels, Belgium, grant number ECHO/COD/BUD/2018/91023). This Article covers humanitarian aid activities implemented with the financial assistance of the EU. The views expressed herein should not be taken, in any way, to reflect the

official opinion of the EU, and the European Commission is not responsible for any use that might be made of the information it contains. We thank the caregivers and children who participated in the study. We also thank the ALIMA operational team in the Democratic Republic of the Congo who managed the trial and the nutrition programme on a day-to-day basis. We thank the Ministry of Health of the Democratic Republic of the Congo through the commitment of key representatives from the Kamuesha Health Zone and the National Nutrition Programme. We acknowledge the implementing partners of the interagency Nutrition Cluster Kasai Province, in particular representatives from UNICEF and the World Food Programme. We also thank Valérie Journot (INSERM UMR 1219, Bordeaux, France) and Claire Levy-Marchal (ALIMA, Paris, France) for advising the study team on the trial methodology, and Aurélie Beuscart and Sophie Karcher (INSERM UMR 1219, Bordeaux, France) for advising the study team on data management and information technology procedures. This study was developed as part of the Clinical and Operational Research Alliance (CORAL). The aim of this research platform is to develop high-quality innovative and transformative research programmes through a partnership between scientists from the research institute INSERM (Institut National de la Santé et la Recherche Médicale, Bordeaux, France, and Abidjan, Côte d'Ivoire) and the humanitarian organisation ALIMA (Paris, France, and Dakar, Senegal), primarily on improving maternal and child health outcomes. A board of directors defines the scientific policy of the CORAL partnership, along with the supervision of research projects and dissemination of results. It consists of senior representatives from both ALIMA and INSERM: Renaud Becquet (INSERM, Bordeaux, France), Susan Shepherd (ALIMA, Dakar, Senegal), Augustin Augier (ALIMA, Paris, France), Moumouni Kinda (ALIMA, Dakar, Senegal), Marie Jaspard (ALIMA and INSERM, Abidjan, Côte d'Ivoire), Claire Levy-Marchal (ALIMA, Paris, France), and Xavier Anglaret (INSERM, Bordeaux, France, and Abidjan, Côte d'Ivoire). The CORAL research platform meets annually with an external scientific advisory board to review projects and strategic orientation. Finally, we thank the members of the data safety monitoring board for the OptiMA-DRC trial: Yves Martin-Prevel (chair, French National Institute for Sustainable Development, MoISA team, University of Montpellier, Montpellier, France), Matthew Coldiron (Epicentre, New York, NY, USA), and Katia Castetbon (statistician, School of Public Health, Université Libre de Bruxelles, Bruxelles, Belgium)

Cost-effectiveness of a simplified acute malnutrition program: a secondary analysis of the OptiMA randomized clinical trial in the Democratic Republic of the Congo

Abstract

Acute malnutrition (AM) causes large loss of life and disability in children in Africa. Researchers are testing innovative approaches to increase efficiency of treatment programs. This paper presents results of a cost-effectiveness analysis of one such program in the Democratic Republic of the Congo (DRC) based on a secondary analysis of a randomized controlled trial Optimizing Treatment for Acute Malnutrition (OptiMA), conducted in DRC in 2018-20. 896 children aged 6-59 months with a mid-upper arm circumference (MUAC) <125 mm or with oedema were treated and followed for six months. Cost-effectiveness of OptiMA using ready-to-use therapeutic food (RUTF) at a tapered dose was compared with the standard national program in which severe cases (SAM) received RUTF proportional to weight, and moderate cases (MAM) were referred to another clinic for a fixed dose regimen of ready-to-use supplementary food. Cost analysis from provider perspective used data collected during the trial and from administrative records. Statistical differences were derived using t-tests. The mean cost per enrolled child under OptiMA was \$123 [95%CI: 114-132], not statistically different from the standard group (\$127 [95%CI: 118-136], $p=0.549$), while treatment success (i.e. recovery to MUAC > 125mm and no relapse for 6 months) under OptiMA was 9 percentage points higher (72% vs 63%, $p=0.004$). Among children with SAM at enrollment, there was no significant difference in treatment success between OptiMA and standard (70% vs 62%, $p=0.12$) but OptiMA's mean cost per enrolled child was 23% lower (\$128 vs \$166, $p<0.0001$). OptiMA was more effective at preventing progression to SAM among those enrolled with MAM (5% vs 16%, $p<0.0001$) with an incremental cost-effectiveness ratio (ICER) of \$234 per progression to SAM prevented. Overall, OptiMA had significantly better outcomes and was no more expensive than standard care. Its adoption could enable more children to be successfully treated in contexts where therapeutic food products are scarce.

ACCEPTED MANUSCRIPT

Introduction

Malnutrition is endemic in many parts of the world today, with 149 million children under five stunted and at least 45 million wasted (UNICEF et al., 2021). The Democratic Republic of the Congo (DRC) has one of the largest malnutrition problems, because of disease burden, poor diet, and poverty, aggravated by conflict (World Food Programme, 2018). UNICEF estimates over 3 million children under five suffered from acute malnutrition in DRC in 2021 (UNICEF, 2021).

Even though effective interventions exist, national malnutrition programs face substantial financial constraints, and thus fewer than 30% of malnourished children currently access to treatment (No Wasted Lives, 2019; World Food Programme, 2018), due to a mix of supply-side and demand-side constraints. This jeopardizes achievement of global nutrition targets for 2025 of reducing the number of stunted children to 100 million (World Health Organization, 2014) and the Sustainable Development Goal of zero hunger by 2030 (United Nations, 2021). In addition to mobilizing additional resources for prevention and treatment, innovations to improve the efficiency of acute malnutrition (AM) treatment are needed to make scarce available resources go further.

The standard approach to addressing AM divides malnourished children into severe (SAM: MUAC <115 mm and/or WHZ <-3, and/or presence of edema) and moderate (MAM: MUAC between 115 mm and 125 mm and WHZ \geq -3Z) and treats them in separate programs using different nutritional products supplied by parallel supply chains, which complicates logistics and coordination of service delivery. Furthermore, treatment for MAM is endorsed by WHO only in contexts limited to severe food insecurity or conflict and is thus often unavailable alongside SAM programming (WHO, 2017).

The Optimizing Treatment for Acute Malnutrition (OptiMA) trial conducted in DRC in 2018-20 (clinical trials.gov NCT03751475) (Cazes et al 2022; Cazes et al 2023). OptiMA aims to improve efficiency of resource use and maintain the continuity and effectiveness of treatment by defining eligibility for treatment as mid-upper arm circumference (MUAC) of less than 125mm, or clinical detection of nutritional edema. This shortens the time taken to determine whether children are eligible for treatment and lowers resource requirements by involving only one health worker instead of the two needed to measure both MUAC and WHZ under the prevailing standard nutrition guidelines in DRC..

OptiMA uses a single product (RUTF) and tapers the dose as weight and MUAC increase. The standard national approach in DRC treats SAM patients with an increasing RUTF dose as the child gains weight and MAM patients with a fixed dose (500 kcal/day) of ready-to-use supplementary food (RUSF) regardless of weight¹. The simplified OptiMA approach, which offers a “one-stop shop” for AM treatment, is designed to improve the cost-effectiveness of treatment by reducing the logistical complexity and corresponding quantity of labor and RUTF used per course of treatment, while still aiming to maintain effectiveness as measured through nutritional outcome indicators.

The primary outcome of the study was the success rate, defined as alive, not acutely malnourished, without relapse during the 6-month period after the initiation of the program. Cazes et al. (2022) found that the success rate among children in the OptiMA group was 9.0 percentage points higher than that in the standard group (95% CI 2.0 to 15.9).

In this paper, we examine the cost of treatment strategies in the trial and measure the overall cost-effectiveness of OptiMA in terms of cost per additional successfully treated case, the probability OptiMA is cost-effective, and, among the subset of patients with MAM at enrollment, the cost per episode of progression from MAM to SAM.

Methods

Study Design and Participants

This study is a secondary analysis of a randomized controlled trial called Optimizing Treatment for Acute Malnutrition (OptiMA), conducted in Kamuesha health zone, Kasai Province, Democratic Republic of Congo (DRC) in 2019-2020. Kamuesha is a remote district of 500,000 people with 26 health centres and one district hospital. In 2019, this landlocked rural health zone experienced persistent armed conflict, population displacement, and substantial food insecurity. The malnutrition treatment project that hosted the trial was implemented by the Alliance for International Medical Action (ALIMA), a non-governmental organization (NGO). Over seven months beginning July 22, 2019, the trial enrolled 896 children aged 6-59 months with a MUAC less than 125mm or with oedema (Cazes et al., 2022). These 896 children were only the fraction of all children admitted to the 26 health centres in the study. This is because one of the purposes of the OptiMA trial was to conduct non-inferiority analysis among SAM children, while the majority of admitted children were MAM and thus the study stopped enrolling MAM while ensuring the sufficient sample of SAM children.

¹ RUTF was manufactured by Nutriset, Hameau du Bois Ricard - CS 80035 - 76770 Malaunay – France, and purchased by UNICEF. RUSF was from the same manufacturer and provided by the World Food Programme.

Trial Design

The individual-level randomized controlled trial was launched on May 1, 2018, with children randomized 1:1 to either the standard or OptiMA arm. Inclusion criteria included all children living in the trial catchment area, aged between 6 and 59 months, with a mid-upper arm circumference (MUAC) of less than 125 mm, bilateral oedema, or WHZ score of less than -3. Exclusion criteria were medical conditions requiring hospitalization; no appetite; grade 3 oedema; known allergy to milk, peanuts, or RUTFs; any chronic pathology; MUAC of 125 mm or larger with no bilateral oedema but a WHZ score of less than -3; and siblings of children already randomly assigned in the trial. Although children who required inpatient care at the outset were not enrolled, those who deteriorated to the point where they required inpatient care were included in the overall analysis.

The final sample sizes in the standard group and OptiMA were 446 and 450, respectively. Sex data were collected based on self-reporting and the options were either female or male. In the sample, the proportion of female was 50% and 51% for standard group and OptiMA, respectively. Study children were further categorized into two groups according to initial nutritional status based on the WHO definition: moderate acute malnutrition (MAM: MUAC 115-125 mm and WHZ \geq -3Z) and severe acute malnutrition (SAM: MUAC <115 mm and/or WHZ <-3, and/or presence of edema). See Cazes et al. (2022) Figure 1 for the trial profile.

Table 1 summarizes the differences in program design between the OptiMA and standard arms. For the latter, children with SAM received ready-to-use therapeutic food (RUTF) at a weight-based dosage with the amount increasing as the child's weight increased. Children in the OptiMA group, regardless of nutritional status (SAM or MAM), received RUTF at a dosage that gradually decreased as the child's weight and MUAC increased.

RUTF and RUSF supplementation in both the standard and OptiMA groups was stopped once children reached the recovery state, defined as achieving MUAC \geq 125mm in OptiMA or, MUAC \geq 125mm or weight-for-height z-score \geq -1.5 in the standard group without oedema for two consecutive weeks, in good clinical health, i.e., an axillary temperature below 37.5 Celsius, and enrolled in the program for at least 4 weeks.

The progress of children in the trial was monitored weekly at health centres for the duration of supplementation and then via bi-monthly home visits for 6 months after inclusion. MUAC and weight were recorded at each visit and height once per month. Treatment for illnesses such as respiratory infection, diarrhea, and malaria (and the medications prescribed) and the quantity of RUTF sachets provided was also noted. If children were admitted for inpatient care, their health condition, medications, and the quantity of RUTF consumed were recorded daily. The total amount of RUSF from the beginning to the end of the program for each child was recorded.

At study conclusion, children were classified as having either a favorable or unfavorable outcome at 6 months, defined as: child alive, not acutely malnourished, and no additional episode of acute malnutrition (relapse) throughout the 6-month period following inclusion (Cazes et al., 2020). "Not acutely malnourished" was defined as MUAC \geq 125 mm, WHZ \geq -3, and absence of bilateral nutritional oedema.

Cost and Cost-Effectiveness Analysis

Costing of the malnutrition treatment approaches in each of the OptiMA-DRC trial arms was conducted retrospectively using clinical data collected during the trial and administrative records documenting

resource use and expenditures, using bottom-up ingredients approach. Cost estimates include provider and patient costs.

Total treatment cost for each study arm was calculated by multiplying the quantity of each resource used by its unit cost and summing across resource categories. Four broad categories of resources were identified: service utilization, nutritional commodities, general medications, and supply chain. Service utilization included outpatient clinic visits, outpatient home visits, and inpatient clinic care. Costs of outpatient and inpatient visits were calculated based on labor used and other inputs recorded in ALiMA's expense book. Medications and tests used included Vitamin A, mebendazole for deworming, rapid malaria test, and amoxicillin for bacterial infection among SAM children, Artemether-lumefantrine (AL) for malaria-positive children, and Nystatin for oral candidiasis among SAM children. Price information for medications was obtained from Médecins Sans Frontières for 2021-2022.

Costs for supply chain logistics included transportation costs to distribute RUTF/RUSF and medications (local and international freight, vehicular transport to clinics), labor costs for procurement and warehousing, drivers, and office space. The unit price for supply chain was the total logistic costs divided by the total number of children. The standard arm program uses two distinct supply chains managed by different organizations, one for RUTF and another for RUSF. Because the OptiMA program would only require one supply chain, we assumed a proportional reduction in cost due to consolidation of warehouse space, reduced complexity of inventory management, and fewer deliveries. We assumed a 35% reduction in cost due to consolidation of warehouse space, reduced complexity of inventory management, and fewer deliveries. We tested this assumption in sensitivity analysis.

The main outcome metric for our cost-effectiveness analysis is the incremental cost-effectiveness ratio (ICER), expressed as the cost required to obtain an additional successfully treated patient. We conducted t-tests to compare the total cost per child enrolled and effectiveness between the OptiMA group and the standard group and reported p-values. We reported the mean, median, and interquartile range (ICR) of costs by looking at the distribution of costs estimates. Where an intervention had equal or better effectiveness and lower cost than a comparator, it was considered dominant and an ICER was not computed. Instead, we reported the magnitude of cost savings per patient treated. When an intervention was dominant, we also calculated the average cost effectiveness ratio (ACER) of each strategy and reported the cost difference per successfully treated patient

During the trial, most of the patients (62%) in the standard arm with a diagnosis of MAM at enrollment did not receive MAM treatment per protocol due to stockouts of RUSF. For this reason, we examined cost-effectiveness overall and separately for patients enrolled with SAM and MAM.

We conducted three sensitivity analyses. First, we conducted probabilistic sensitivity analysis, which simultaneously considered the uncertainties in the quantities of resources used based on observed variation across patients in the trial. We used bootstrapping methods (Obenchain, 1999) to construct 10,000 simulated datasets by sampling from the original trial data with replacement. For each simulated dataset, we computed the mean and median cost for OptiMA and national protocol, as well as the portion of cases successfully treated. From this analysis, we calculated the probability that OptiMA is cost-saving and the probability OptiMA is cost-effective, as compared to the standard of care. Second, we explored how the magnitude of assumed savings on supply chain logistics affected overall cost and cost-effectiveness. Third, we evaluated variations in the unit costs for outpatient visits, home visits, inpatient stays, and supply chain logistics in one-way sensitivity analysis.

The probability an AM treatment intervention is cost-effective depends not only on its incremental costs and treatment effectiveness, but also on how much an additional unit of benefit is worth. To analyze this, we used a cost-effectiveness acceptability curve to show the probability that OptiMA is cost-effective as a function of willingness-to-pay. Since benchmark thresholds for cost-effectiveness in resource-limited settings are usually measured in cost per disability-adjusted life years (DALYs) averted, we converted AM treatment success to DALYs disability-adjusted life year (DALY) averted. Previous studies of similar AM treatment interventions reported averting 1.2 to 5.4 DALYs per child successfully treated (Goudet et al., 2018), (Shekar et al., 2016), (Bachman, 2009; Jenkins, 2013; Wilford et al., 2012), (Puett et al., 2013). In our ICER calculations we therefore explored a range of 0-5 DALYs averted per successfully treated case.

Benchmark thresholds for cost-effectiveness in low-income countries typically range from 0.25 to 1.0 times GDP per capita per disability-adjusted life-year (DALY) averted (Woods 2016, Edeka 2020). Since DRC's GDP per capita is \$560 (World Bank, WDI), we considered the threshold for cost-effectiveness in DRC to be between \$140 and \$560 per DALY averted.

Data analysis was conducted using Stata SE15.1.

Results

Table 2 presents the unit price for each of the five broad categories of resources. The unit price was \$3.45 for an outpatient clinic visit, \$5.13 for a home visit, and \$34.72 for an inpatient day (Appendix 1). The unit price of RUTF and RUSF was \$0.28 and \$0.26 per sachet respectively, excluding transportation cost (Cazes et al. 2022). The unit price for supply chain per child enrolled was \$13.83. Appendix 2 presents the breakdown of supply chain costs.

Table 3 presents the summary statistics of children in the sample. At inclusion, the mean age was 20.1 months (SD: 12.7). The numbers of girls and boys were nearly equal. The mean MUAC was 118mm (SD:6.3) and 8.7% (78/896) had oedema. The mean weight and height was 7.6kg (SD: 1.8) and 73.4cm (SD: 9.4), respectively. About 19 percent of children (170 /896) had Weight-for-Height z-score less than -3.

Table 4 presents the summary statistics on the quantity of resources used. Children enrolled in the OptiMA arm had a mean of 7.9 clinic visits (SD: 4.4), versus 5.3 (SD: 5.1) in the standard arm. Among children initially enrolled with SAM, the number of clinic visits was similar (8.73 (SD: 4.80) in standard, 8.54 (SD: 4.53) in OptiMA).

Home visits were conducted 8.8 times (SD: 3.0) for children for the standard and 7.5 times (SD: 2.6) for the OptiMA arms. A total of 7% (32/446) and 10% (43/450) of patients were hospitalized in the standard and OptiMA arms, respectively. When hospitalization did occur, the duration was 7.6 days (SD: 4.3) for standard and 7.1 days (SD: 4.4) for OptiMA.

For patients initially enrolled with SAM, the mean amount of RUTF distributed per child was 181 sachets (SD: 101) in the standard group and 99 sachets (SD: 60) for OptiMA. In OptiMA, patients enrolled with MAM received a mean of 69 RUTF sachets (SD: 46). Patients in the standard arm were supposed to receive RUSF, but lack of continuous supply resulted in only 36% (88/246) receiving any RUSF. Among this subset of patients, the mean was 27.3 sachets (SD: 10.5).

In the standard arm, the malnutrition status of 40/246 (16%) children with MAM at inclusion worsened to the point of qualifying for SAM treatment. They were treated with RUTF at an average of 170.1 sachets

per child (mean). In contrast, only 12 of 252 (5%) of patients enrolled in the OptiMA arm with MAM worsened to SAM.

All children received Vitamin A, deworming medication, malaria diagnostic tests, and those categorized as SAM upon inclusion received amoxicillin for bacterial infection and nystatin for oral candidiasis if necessary. A large share of children (77%; 683/896) received malaria treatment in both arms.

Overall, there was no significant difference in the total cost per child enrolled at \$126.5 and \$122.6 (p=0.55) in the standard and OptiMA arms, respectively (Table 5). However, all children in OptiMA and those enrolled with SAM in the standard group received RUTF, whereas only 38% of those enrolled with MAM in the standard group received the indicated RUSF, due to stock outs. The remaining 62% did not receive RUSF or other treatment. When restricting the analysis to patients enrolled with SAM, fewer resources were used in every category for the OptiMA group compared to standard arm, with total cost per child 23% lower with OptiMA (\$166.1 standard vs. \$127.9 OptiMA). Among children enrolled with MAM, the total cost was 25% higher with OptiMA (\$94.7 standard vs \$118.5 OptiMA).

In the trial, OptiMA was significantly more effective than the standard national protocol at producing recovered patients without relapse at 6 months. Patients in the OptiMA arm had a 9-percentage point higher treatment success rate (72% vs. 63%). Since OptiMA was no more expensive than the standard group, but was more effective, OptiMA was a dominant strategy (Table 6). A comparison of the ACER for each strategy showed that the OptiMA cost \$31 less per successful outcome.

OptiMA did not categorize patients into SAM and MAM. But because the standard arm did, it can be useful to analyze outcomes for these groups separately to better understand the drivers of cost-effectiveness. Among children enrolled with SAM, OptiMA was a dominant strategy: no less effective (0.70 vs. 0.62; p<0.12) and \$38.21 less expensive per enrolled patient than the standard (p<0.0001). A comparison of the ACER for each strategy showed that the OptiMA cost \$85 less per successful outcome.

Among children enrolled with MAM, the incidence of children deteriorating to SAM (average 74 days) in the standard group was more than three times higher than with OptiMA (16% vs 5%; p<0.0001). While OptiMA was more effective at preventing progression to SAM, it was more expensive, even after accounting for the additional cost of treating SAM among those patients with progression, due in large part to the fact that 64% (159/246) standard arm patients enrolled with MAM received no RUSF treatment. Among patients enrolled with MAM, OptiMA cost an additional \$234 for each case of progression to SAM prevented as compared to the standard arm.

Sensitivity Analysis

Probabilistic sensitivity analysis was conducted to account for uncertainty in the resource use and treatment success probabilities. Results (Figure 1) show that there is a 99% chance that OptiMA is more effective than the status quo implementation of the national protocol and a 71% chance that it is also cost-saving. Additionally, there is a 92% chance that the median cost of OptiMA is lower than the median cost of the national protocol.

If OptiMA were not cost-saving, the probability that it is cost-effective would depend on the threshold for good value – that is, how many disability-adjusted life years (DALYs) are averted by successfully treating a case of AM, and what that health benefit is worth. The cost-effectiveness acceptability curve shown in Figure 2 indicates that even with as little as 0.5 DALY averted per successfully treated AM case the OptiMA strategy is very likely to be cost-effective compared to the status quo national protocol, with a

98% chance of having an ICER less than a cost-effectiveness threshold of \$140 (25% of GDP per capita) per DALY averted. In one-way sensitivity analysis, we varied the mean costs of clinic visit, home visit, and hospitalization between 50% and 200% of the base case (Appendix 4). We also tested the relative efficiency of supply chain costs, using zero efficiency gain at one extreme (supply chain cost the same in OptiMA and standard) (Appendix 3) and 50% efficiency gain at the other extreme. Results of OptiMA's dominance or cost-effectiveness using different scenarios as part of sensitivity analyses did not change from the base case. Out of eight scenarios, five still concluded that OptiMA was a dominant strategy. If the cost of clinic visits was assumed to be twice those in our base case, OptiMA became more expensive but still cost-effective with ICER of \$57 per successfully treated case, assuming successfully treating a case results in at least 0.5 DALY averted. If supply chain cost was identical for OptiMA and standard, then the total cost per child enrolled was only slightly higher under OptiMA (\$123.06 vs \$122.09), and the ICER for OptiMA vs. standard was \$10.7 per successfully treated case.

Discussion

Given the heavy burden of acute malnutrition in children in sub-Saharan Africa and South Asia, financing shortfalls, and constrained supply of therapeutic foods, there is a pressing need to find more efficient treatment approaches. The results of this analysis indicate that OptiMA is likely one such approach. In the DRC trial, OptiMA was a dominant strategy compared to the status quo, because it was more effective and no more costly. When focusing on patients enrolled with SAM, we found that the OptiMA approach was no less effective and reduced cost by 23%, saving \$38 per person treated. Additionally, the probability of deteriorating from MAM to SAM in OptiMA was lower compared to the standard national protocol for DRC.

Our analysis shows that the mean cost per child enrolled in the OptiMA and standard groups was similar at \$123 and \$127, respectively. OptiMA's unified approach to treating all severity levels of acute malnutrition resulted in a similar overall cost per child enrolled as the standard approach but the allocation of resources across patients was different in the two arms. The OptiMA group had higher costs for clinic visits while the standard group had higher costs for home visits because the OptiMA was functioning at all times and patients were more likely to comply with the intervention and come back for the clinic visit for follow-up, while the standard approach had supply-side challenges and children were more likely to be followed at their home. The OptiMA group had higher hospitalization costs per child enrolled but lower costs on RUTF.

The OptiMA program costs less than the standard approach per child enrolled with SAM, but more per child enrolled with MAM. The result among SAM patients is promising but will benefit from further studies to replicate this finding. When focusing on children enrolled with SAM, the mean cost for the OptiMA and standard groups was \$128 and \$166, respectively, largely due to the lower quantity of RUTF per patient under OptiMA. These findings are similar to those in other studies using shorter follow-up times, with a mean cost per child ranging from \$166-314 in 2020 USD for the treatment of AM (reported in Njuguna et al., 2020).²

² Mean cost per child of \$166 in 2020 USD in Uganda (Jenkins, 2013), \$216 to 248 in 2020 USD in India (Menon et al., 2016; Garg et al., 2018), and \$292 in 2020 USD in Indonesia (Purwestri et al., 2012); community-based treatment cost of \$168 in 2020 USD per child in Ethiopia (Tekeste et al., 2012), \$196 in 2020 USD in Bangladesh (Puett et al., 2013), 149 euros (or \$220 in 2020 USD) in Niger (Isanaka et al., 2016), \$226 in 2020 USD in Zambia (Bachmann, 2009), and \$314 in 2020 USD in Pakistan (Rogers et

In our study, among patients enrolled with MAM, OptiMA provided treatment to a much larger portion of patients, was more effective at producing recovered patients without relapse at 6 months, and greatly reduced risk of progression to SAM. Although the standard approach saved resources by leaving untreated more than half of the children enrolled with MAM, this had negative consequences as shown through the higher rate of deterioration to SAM (16% with the standard approach versus 5% with OptiMA).

Improved outcomes for MAM patients are an important benefit of the OptiMA approach. Previous studies have estimated that children with MAM have 2.5 times higher mortality than well-nourished children after discharge from hospital (Diallo et al., 2022), and are more susceptible to diseases that cause substantially higher risk of mortality and morbidity. Treatment of MAM reduces the chance of relapses, deterioration to SAM, and death (Chang, 2012).

Limitations of our study include a small sample size and the lack of long-term follow-up to observe the cumulative impact and broader set of long-term consequences of programs for treating AM episodes that may recur through childhood, while the follow-up period in this study is longer than many other studies. Another limitation is the poor adherence to the national protocol, resulting in lack of treatment, among more than half of MAM children under the standard group. We do not know what the cost or effectiveness of the national protocol would have been if the MAM programme had been functioning with a stable supply of RUSF. However, our results capture the real-world implementation challenges facing such programs. Uncertainty regarding the impact of adopting OptiMA on the efficiency of the supply chain is a further limitation. In the context of a single randomized control trial, we could not measure the amount of cost-savings that might accrue from consolidating supply chains in a large-scale program with RUTF used as the only therapeutic food product for all patients. However, even if our assumption of a 35% reduction in supply chain cost turns out to be too large, our conclusions from this study are not sensitive to this uncertainty. Assuming no gains in supply chain efficiency from eliminating the RUSF supply channel, OptiMA would still have a highly favorable ICER of \$9 per additional case successfully treated.

OptiMA had significantly better outcomes and was no more expensive than standard care. Its adoption could enable more acutely malnourished children to be successfully treated in contexts where therapeutic food products are scarce.

References

- Bachmann MO. Cost effectiveness of community-based therapeutic care for children with severe acute malnutrition in Zambia: decision tree model. *Cost Effectiveness and Resource Allocation*. 2009 Dec; 7:1-9.
- Cazes C, Phelan K, Hubert V, Alitanou R, Boubacar H, Izie Bozama L, Tshibangu Sakubu G, Beuscart A, Yao C, Gabillard D, Kinda M, Augier A, Anglaret X, Shepherd S, Becquet R. Simplifying and optimising management of acute malnutrition in children aged 6 to 59 months: study protocol for a community-based

al., 2019). These studies mainly focused on SAM children, except for Jenkins (2013) which included both SAM and MAM and Purwestri et al. (2012) which focused on MAM.

individually randomised controlled trial in Kasai, Democratic Republic of Congo. *BMJ Open*. 2020 Dec 2;10(12):e041213. doi: 10.1136/bmjopen-2020-041213. PMID: 33268424.

Cazes C, Phelan K, Hubert V, Boubacar H, Bozama LI, Sakubu GT, Tshiala BK, Tusuku T, Alitanou R, Kouamé A, Yao C. Simplifying and optimising the management of uncomplicated acute malnutrition in children aged 6–59 months in the Democratic Republic of the Congo (OptiMA-DRC): a non-inferiority, randomised controlled trial. *The Lancet global health*. 2022 Apr 1;10(4): e510-20.

Cazes C, Phelan K, Hubert V, Boubacar H, Bozama LI, Sakubu GT, Senge BB, Baya N, Alitanou R, Kouamé A, Yao C, Gabillard D, Daures M, Augier A, Angleret X, Kinda M, Shepherd S, Becquet R. Optimising the dosage of ready-to-use therapeutic food in children with uncomplicated severe acute malnutrition in the Democratic Republic of the Congo: a non-inferiority, randomised controlled trial. *eClinicalMedicine*. 2023 Feb 28; 58, 101878.

Chang CY, Trehan I, Wang RJ, Thakwalakwa C, Maleta K, Deitchler M, Manary MJ. Children successfully treated for moderate acute malnutrition remain at risk for malnutrition and death in the subsequent year after recovery. *The Journal of nutrition*. 2013 Feb 1;143(2):215-20.

Cobb G, Bland RM. Nutritional supplementation: the additional costs of managing children infected with HIV in resource-constrained settings. *Tropical Medicine & International Health*. 2013 Jan;18(1):45-52.

Diallo AH, Shahid AS, Khan AF, Saleem AF, Singa BO, Gnoumou BS, Tigoi C, Otieno CA, Bourdon C, Oduol CO, Lancioni CL. Childhood mortality during and after acute illness in Africa and south Asia: a prospective cohort study. *The Lancet Global Health*. 2022 May 1;10(5): e673-84.

Edoka IP, Stacey NK. Estimating a cost-effectiveness threshold for health care decision-making in South Africa. *Health Policy Plan*. 2020 Jun 1;35(5):546-555. doi: 10.1093/heapol/czz152. PMID: 32125375.

Garg CC, Mazumder S, Taneja S, Shekhar M, Mohan SB, Bose A, Iyengar SD, Bahl R, Martinez J, Bhandari N. Costing of three feeding regimens for home-based management of children with uncomplicated severe acute malnutrition from a randomised trial in India. *BMJ Global Health*. 2018 Mar 1;3(2): e000702.

Goudet, Sophie, A. Jayaraman, S. Chanani, D. Osrin, Brecht Devleesschauwer, Barry Bogin, N. Madise, and Paula Griffiths. "Cost effectiveness of a community based prevention and treatment of acute malnutrition programme in Mumbai slums, India." *PLoS One* 13, no. 11 (2018): e0205688.

Isanaka S, Menzies NA, Sayyad J, Ayoola M, Grais RF, Doyon S. Cost analysis of the treatment of severe acute malnutrition in West Africa. *Maternal & child nutrition*. 2017 Oct;13(4): e12398.

Jenkins GP. A cost-effectiveness analysis of acute malnutrition treatment using ready to use therapeutic foods. Cambridge Resources International INC: JDI Executive Programs. 2013 Jan.

Menon P, McDonald CM, Chakrabarti S. Estimating the cost of delivering direct nutrition interventions at scale: national and subnational level insights from India. *Maternal & child nutrition*. 2016 May; 12:169-85.

Njuguna RG, Berkley JA, Jemutai J. Cost and cost-effectiveness analysis of treatment for child undernutrition in low-and middle-income countries: a systematic review. *Wellcome Open Research*. 2020 Oct 5; 5:62.

No Wasted Lives (2019) The State of Acute Malnutrition. Available at <https://acutemalnutrition.org/en/countries> (accessed Nov 29, 2022).

Obenchain, RL. Resampling and multiplicity in cost-effectiveness inference. *J Biopharm Stat* 1999. 9(4):563-582.

Puett C, Sadler K, Alderman H, Coates J, Fiedler JL, Myatt M. Cost-effectiveness of the community-based management of severe acute malnutrition by community health workers in southern Bangladesh. *Health policy and planning*. 2013 Jul 1;28(4):386-99.

Purwestri RC, Scherbaum V, Inayati DA, Wirawan NN, Suryantan J, Bloem MA, Pangaribuan RV, Hoffmann V, Biesalski HK, Qaim M, Bellows AC. Cost analysis of community-based daily and weekly programs for treatment of moderate and mild wasting among children on Nias Island, Indonesia. *Food and Nutrition Bulletin*. 2012 Sep;33(3):207-16.

Rogers E, Guerrero S, Kumar D, Soofi S, Fazal S, Martínez K, Morán JL, Puett C. Evaluation of the cost-effectiveness of the treatment of uncomplicated severe acute malnutrition by lady health workers as compared to an outpatient therapeutic feeding programme in Sindh Province, Pakistan. *BMC public health*. 2019 Dec; 19:1-1.

Tekeste A, Wondafrash M, Azene G, Deribe K. Cost effectiveness of community-based and in-patient therapeutic feeding programs to treat severe acute malnutrition in Ethiopia. *Cost Effectiveness and Resource Allocation*. 2012 Dec;10(1):1-0.

United Nations Children's Fund (UNICEF), World Health Organization, International Bank for Reconstruction and Development/The World Bank. Levels and trends in child malnutrition: key findings of the 2021 edition of the joint child malnutrition estimates. Geneva: World Health Organization; 2021. License: CC BY-NC-SA 3.0 IGO.

World Food Programme (2018) WFP and Nutrition. Available at <https://docs.wfp.org/api/documents/WFP-0000099337/download/> (accessed Nov 29, 2022).

World Health Organization. *Global nutrition targets 2025: policy brief series (WHO/NMH/NHD/14.2)*. Geneva: World Health Organization. 2014.

World Health Organization (2017). *Guideline: assessing and managing children at primary health-care facilities to prevent overweight and obesity in the context of the double burden of malnutrition: Updates for the integrated management of childhood illness*. Available at <https://www.who.int/publications/i/item/9789241550123> (accessed Oct 26, 2022).

Shekar, Meera, Julia Dayton Eberwein, and Jakub Kakietek. "The costs of stunting in South Asia and the benefits of public investments in nutrition." *Maternal & Child Nutrition* 12 (2016): 186-195.

Wilford, Robyn, Kate Golden, and Damian G. Walker. "Cost-effectiveness of community-based management of acute malnutrition in Malawi." *Health policy and planning* 27, no. 2 (2012): 127-137.

Woods, Beth, Paul Revill, Mark Sculpher, and Karl Claxton. "Country-level cost-effectiveness thresholds: initial estimates and the need for further research." *Value in Health* 19, no. 8 (2016): 929-935.

World Bank. 2019. "Life expectancy at birth, total (years)" available at <https://data.worldbank.org/indicator/SP.DYN.LE00.IN?locations=CD>

World Bank. 2020. GDP per capita (current US\$). Available at <https://data.worldbank.org/indicator/NY.GDP.PCAP.CD?locations=CD>

ACCEPTED MANUSCRIPT

Legends

Figure 1: Sensitivity Analysis





Figure 2: Cost-effectiveness acceptability curves for different assumptions about the DALYs averted per successfully treated acute malnutrition case.



DALY per Successfully Treated AM Case	0	0.5	1	2
Threshold WTP per DALY averted				
\$0 (i.e. program must be cost-saving)	71%	71%	71%	71%
\$70 (0.125 * GDP per capita)	71%	84%	92%	98%
\$140 (0.25 * GDP per capita)	71%	92%	98%	100%
\$280 (0.5 * GDP per capita)	71%	98%	100%	100%
\$560 (1.0 * GDP per capita)	71%	100%	100%	100%

Table 1: OptiMA-DRC Trial Design

Table 2: Unit cost for utilization of services, commodities, and resources (US dollars, 2020)

Table 3. Baseline characteristics

Table 4: Quantity of resources used per patient (mean)

Table 5: Cost per child enrolled (US dollars, 2020)

Table 6: Cost-effectiveness Results

Appendix 1: Breakdown of Unit Cost (US dollars, 2020)

Appendix 2: Breakdown of Supply Chain Costs (US dollars, 2020)

Appendix 3: Sensitivity Analysis for No Supply Chain Cost Savings Scenario: Cost estimate and ICER

Appendix 4: Sensitivity Analysis – Cost variation

Tables

Table 1: OptiMA-DRC Trial Design

	Standard Protocol		OptiMA Protocol		
	MAM	SAM	Acute malnutrition		
Wasting definition	MUAC 115-124mm Or $-3 < \text{WHZ} < -2$	MUAC < 115mm Or WHZ < -3 (SD) Or Bipedal oedema	MUAC < 125mm Or Bipedal oedema		
Treatment product & Quantity	RUSF one 92g sachet /d (500Kcal/d)	RUTF 150-200 Kcal/kg/d	170-200 (Kcal/Kg/d) for MUAC < 115mm Or bipedal oedema	125-190 (Kcal/Kg/d) for MUAC 115- 119mm	50-166 (Kcal/Kg/d) for MUAC 115-124mm
Calculation of dosage	Fixed amount, regardless of weight or MUAC status	According to the weight	According to MUAC status and weight		

Note: Based on Casez et al (2021). Kcal: kilocalories corresponding to the dosage of RUTF/RUSF. Kg: kilogram of child's weight. d: day. Kcal/Kg/d describes the dosage amount (Kcal) per each unit of child's weight (kg) per day (d).

Table 2: Unit cost for utilization of services, commodities, and resources (US dollars, 2020)

Category	Unit price in US dollars (2020)	Data source
Service Utilization		
Outpatient clinic visits	3.45	ALIMA's accounting records in 2021; authors' calculation (Appendix 1)
Outpatient home visits	5.13	ALIMA's accounting records in 2021; authors' calculation (Appendix 1)
Inpatient visit cost per day	34.72	ALIMA's accounting records in 2021; authors' calculation (Appendix 1)
Nutritional Commodities		
RUTF (one sachet)	0.28	Cazes et al. (2022) (Appendix 1)
RUSF (PlumpySup, one sachet)	0.26	Cazes et al. (2022) (Appendix 1)
Medications		
Vitamin A	0.05	MSF supply (2022)
Deworming	0.06	MSF supply (2022)
Malaria diagnosis	0.7	MSF supply (2022)
Bacterial infection	0.77	MSF supply (2022)
Malaria treatment	0.28	MSF supply (2022)
Oral candidiasis	0.56	MSF supply (2022)
Supply chain	Standard OptiMA	
Supply chain per child	13.83 9.1	ALIMA's accounting records in 2021;

Table 3. Baseline characteristics

	Total		SAM at enrollment		MAM at enrollment	
	Standard N=446	OptiMA N=450	Standard N=200	OptiMA N=198	Standard N=246	OptiMA N=252
Socio-demographic characteristics						
--Male	225 (50%)	221 (49%)	101 (50%)	99 (50%)	123 (50%)	122 (48%)
--Female	221 (50%)	229 (51%)	99 (50%)	99 (50%)	122 (50%)	130 (52%)
--Age (months)	20.6 (12.7)	19.6 (12.7)	21.7 (14.3)	20.2 (13.2)	19.7 (11.2)	19.1 (12.3)
Anthropometric characteristics						
--MUAC (mm)	118 (6.2)	118 (6.3)	115 (7.8)	115 (8.2)	121 (2.5)	120 (2.7)
--Nutritional oedema	43 (10%)	35 (8%)	43 (22%)	35 (18%)	0 (0%)	0 (0%)
--Weight (kg)	7.7 (1.8)	7.6 (1.8)	7.4 (2.1)	7.3 (2.0)	7.9 (1.5)	7.8 (1.7)
--Height (cm)	73.6 (9.2)	73.2 (9.6)	73.8(10.8)	72.9 (10.3)	73.6 (7.8)	73.5 (9.1)
--WHZ <-3	83 (18.6%)	87 (19.3%)	83 (41.5%)	87 (43.9%)	0 (0%)	0 (0%)

Data are mean or n (%). Standard deviations in the parentheses.

Table 4: Quantity of resources used per patient (mean)

	Total		SAM at enrollment		MAM at enrollment	
	Standard (n=446)	OptiMA (n=450)	Standard (n=200)	OptiMA (n=198)	Standard (n=246)	OptiMA (n=252)
Outpatient visits per patient (Number)						
Clinic visits	5.34	7.89	8.73	8.54	2.59	7.37
Home visits	8.84	7.49	7.19	6.86	10.18	7.98
Inpatient Hospitalization						
Probability	0.072	0.096	0.125	0.116	0.028	0.079
Days, per patient hospitalized	7.6	7.1	7.5	6.0	8.0	8.3
Days, per patient	0.55	0.68	0.94	0.70	0.23	0.65
RUTF per patient (sachets)	96.55	82.30	181.29	99.46	27.66	68.82
RUSF (sachets)						
Per patient	5.77	na	0.00	na	10.46	na
Per patient receiving >0 sachet	27.38	na	0.00	na	27.38	na
Treated comorbidity per patient						
Vitamin A	1	1	1	1	1	1
Deworming	1	1	1	1	1	1
Malaria diagnosis	1	1	1	1	1	1
Bacterial infection	0.45	0.44	1	1	0	0
Malaria treatment	0.76	0.77	0.75	0.74	0.76	0.79
Oral candidiasis	0.09	0.09	0.20	0.20	0.00	0.00

Table 5: Cost per child enrolled (US dollars, 2020)

	Standard		OptiMA		SAM at enrollment				MAM at enrollment			
	(n=446)		(n=450)		(n=200)		(n=198)		(n=246)		(n=252)	
	mean	median	mean	median	mean	median	mean	median	mean	median	mean	median
Outpatient visits												
<i>clinic visits</i>	18.42	17.25	27.20	20.7	30.10	24.15	29.47	24.15	8.93	3.45	25.44	20.7
<i>home visits</i>	45.32	46.15	38.39	41.02	36.84	41.02	35.17	35.89	52.22	56.41	40.92	41.02
Hospitalization												
<i>Per patient enrolled</i>	18.99	0	23.47	0	32.81	0	24.37	0	7.87	0	22.73	0
<i>Per patient hospitalized</i>	264.7		245.43		261.06		209.68		277.72		286.4	
RUTF	27.04	28.42	23.04	17.92	50.76	41.16	27.85	22.26	7.75	0	19.27	14.84
RUSF	1.49	0	na	na	0	0	na	na	2.71	0	na	na
Comorbidity treatment												
Local supply chain	1.42	1.09	1.42	1.09	1.91	1.98	1.91	1.98	1.03	1.09	1.03	1.09
	13.83	13.83	9.1	9.1	13.83	13.83	9.1	9.1	13.83	13.83	9.1	9.1
Total	126.52	103.37	122.62	95.55	166.08	123.54	127.86	98.42	94.37	79.91	118.49	91.60
	95% CI	IQR	95% CI	IQR	95% CI	IQR	95% CI	IQR	95% CI	IQR	95% CI	IQR
	[117.48 - 135.57]	79.63; 127.92	[113.55 - 131.68]	87.03; 110.36	[150.14 - 182.03]	114.77; 163.29	[115.76 - 139.96]	92.49; 122.45	[86.19 - 102.54]	73.54; 87.67	[105.33 - 131.65]	85.63; 103.73

ACCEPTED MANUSCRIPT

Table 6: Cost-effectiveness Results

Panel A: Total sample					
	Standard (n=446)	OptiMA (n=450)	Difference	significance, p-value (difference)	ICER (Cost per Success)
Total cost per child enrolled (USD, 2020)	126.52	122.63	-3.89	0.549	
Effectiveness (success rate)	0.63	0.72	0.09	0.0039	OptiMA is dominant
95% CI	[0.59 - 0.68]	[0.68 - 0.76]			
ACER (\$ per success)	200.82	170.31	-30.51		
Panel B: initial SAM					
	Standard (n=200)	OptiMA (n=198)	Difference	p-value	ICER (Cost per Success)
Total cost per child enrolled (USD, 2020)	166.06	127.86	-38.21	<0.0001	
Effectiveness (success rate)	0.62	0.70	0.07	0.13	OptiMA is dominant
95% CI	[0.56 - 0.69]	[0.63 - 0.76]			
ACER (\$ per success)	267.84	182.65	-85.19		
Panel C: initial MAM					
	Standard (n=246)	OptiMA (n=252)	Difference	p-value	ICER (Cost per progression averted)
Total cost per child enrolled (USD, 2020)	94.67	118.49	24.82	0.0022	
Effectiveness (progression to SAM)	0.16	0.05	-0.11	<0.0001	\$234
95% CI	[0.58 - 0.70]	[0.69 - 0.80]			

Notes: Cost is for one additional successfully treated child. Success is defined as being alive, not acutely malnourished, without relapse during the 6-month period after the initiation of the program.

ACER: Average Cost-Effectiveness Ratio, reported in place of ICER to calculate the cost saving per successfully treated patient when an intervention was dominant; ICER: Incremental Cost-Effectiveness Ratio; SAM: severe acute malnutrition; MAM: moderate acute malnutrition

Appendix 1: Breakdown of Unit Cost (US dollars, 2020)

	Cost per child enrolled, US dollars 2020	Notes
Panel A1: Outpatient clinic visits		
labor costs (outpatient) per visit	1.57	<p>“\$352,470/ (115,309 consultations for SAM children + 109,091 general consultations for children under 5 = 224,400 visits during the 30-month study period) \$8590/ month * 30 months = \$257,700 / 224,400 visits (from above). Non-labor costs included office-running costs, utilities, vehicle operation and supplies. The average time for outpatient visit under OptiMA arm is 20 minutes.</p> <p>Transportation costs were opportunity costs of travel time for the caregiver. Most children and caregivers visit the clinic on foot, it takes 3.5 hours on average for transportation. Thus, we used the GDP per capita of \$560 divided by 365 days/yr divided by 8 hours/day = \$0.192 per hour * 3.5 hours.</p>
non labor costs (outpatient)	1.15	
opportunity costs for outpatient visits	0.06	
transportation costs (opportunity costs)	0.67	
Total cost of outpatient clinic visit per child enrolled	3.45	
Panel A2: Outpatient home visits		
labor costs (home visit)	3.12	\$36,414 for 4 nurses, 75% used for 8740 home visits for 1071 children
transportation costs (home visits)	2.00	\$17,505 for motorcycle-related costs (fuel, maintenance, purchase, drivers) for 8740 home visits to 1071 children
Total cost of outpatient home visit per child enrolled	5.13	
Panel B: RUTF / RUSF		
RUTF (1 sachet)	0.28	\$42 for 150 sachets of RUTF
RUSF (PlumpySup, 1 sachet)	0.26	\$38.83 for 150 sachets of RUSF
Panel C: Inpatient visits		
labor costs (inpatient) per day	23.68	\$437,325 for 30 months / (2530 children for 7.3 days), 7.3 days is from the data. Labor costs include costs for ALIMA and MoH.
medications / supplies	9.51	Cost in this category was calculated based on clinician expert opinion regarding the quantity of medicines and supplies (such as antibiotics, needle, syringe, nasogastric tube, oral solution for treatment of dehydration etc.) consumed by typical inpatient case of acute malnutrition. Unit cost of each item was obtained from ALIMA’s accounting records.
opportunity costs per day	1.53	GDP per capita of \$560 divided by 365 days
Total cost of stay per day per child hospitalized	34.72	
Panel D: Supply chain		
	Control	OptiMA
Total cost of supply chain per child enrolled	13.83	9.1
	See Appendix 3 for the breakdown. We assume that the supply chain for RUTF costs the same as the supply chain for RUSF. Because supply chain under control deals with both RUTF and RUSF, it is more expensive than the supply chain cost under OptiMA.	

Note: Aggregated costs and quantities indicated in Notes are based on ALIMA’s accounting records in 2021. Costs reported in Euro were converted to dollars at the 2020 exchange rate 1euro=1.142USD.

Appendix 2: Breakdown of Supply Chain Costs (US dollars, 2020)

Category	Total	Cost per child		Assumptions
		OptiMA	Control	
Local& International freight – medications	3072	0.18	0.18	Same cost between OptiMA and control; \$153,600 for freight of all medications, 2% of which were used for malnourished children.
Vehicles (for distributing medication to clinics)	2655	0.15	0.15	Same cost between OptiMA and control; \$132,750 for vehicles for all medications, 2% of which were used for malnourished children
Labor (procurement, warehouse workers, drivers, etc)	31918	1.87	3.75	cost per child under control is double the cost under OptiMA for 2 parallel supply chain
Local & International freight RUTF	90878	5.34	6.63	shipping cost is proportional to the number sachet
Vehicles (for distributing RUTF to clinics)	7014	0.41	0.82	cost under control is double the cost under OptiMA because of the vehicles for 2 parallel supply chain
Warehouse rent	19790	1.15	2.29	cost per child under control is double the cost under OptiMA for 2 parallel supply chain. Warehouse is for all supplies for all programs, including OptiMA and other programs
	Total	155328	9.10	13.83

Appendix 3: Sensitivity Analysis for No Supply Chain Cost Savings Scenario: Cost estimate and ICER

		Total		SAM at enrollment		MAM at enrollment	
		Control (n=446)	OptiMA (n=450)	Control (n=199)	OptiMA (n=198)	Control (n=247)	OptiMA (n=252)
Outpatient visits							
	clinic visits	18.42	27.20	29.97	29.46	9.12	25.43
	home visits	45.32	38.39	36.88	35.17	52.13	40.92
Hospitalization							
	Per patient enrolled	18.99	23.47	32.81	24.37	7.87	22.73
RUTF		27.04	23.04	50.67	27.85	7.99	19.27
RUSF		1.49	0.00	0.00	0.00	2.70	0.00
Comorbidity treatment							
	<i>Vitamin A</i>	0.05	0.05	0.05	0.05	0.05	0.05
	<i>Deworming</i>	0.06	0.06	0.06	0.06	0.06	0.06
	<i>Malaria diagnosis</i>	0.70	0.70	0.70	0.70	0.70	0.70
	<i>Bacterial infection</i>	0.35	0.34	0.77	0.77	0.00	0.00
	<i>Malaria treatment</i>	0.21	0.21	0.21	0.21	0.21	0.22
	<i>Oral candidiasis</i>	0.05	0.05	0.11	0.11	0.00	0.00
Local supply chain		9.10	9.10	9.10	9.10	9.10	9.10
Total cost per child enrolled (USD, 2020)		121.79	122.63	161.33	127.86	89.94	118.49
Effectiveness (success rate)		0.63	0.72	0.62	0.70	0.64	0.74
ICER			9.33		OptiMA is dominant		279.89

Notes: This sensitivity analysis assumes the supply chain cost is the same under control and OptiMA program.

Appendix 4: Sensitivity Analysis – Cost variation

	Control (n=446)	OptiMA (n=450)	Difference	significance, p-value (difference)	ICER
Total cost per child enrolled (USD, 2020) - default	126.52	122.62	-3.89	0.55	-
50% costs					
Total cost per child enrolled (USD, 2020) - clinic visit cost 50%	117.31	109.01	-8.30	0.18	-
Total cost per child enrolled (USD, 2020) - home visit cost 50%	103.86	103.42	-0.44	0.95	-
Total cost per child enrolled (USD, 2020) - hospitalization cost 50%	117.03	110.89	-6.14	0.13	-

Total cost per child enrolled (USD, 2020) - supply chain cost same (C = T)	121.79	122.62	0.82	0.90	9.12
200% costs					
Total cost per child enrolled (USD, 2020) - clinic visit cost 200%	144.95	149.83	4.87	0.50	54.20
Total cost per child enrolled (USD, 2020) - home visit cost 200%	171.85	161.01	-10.84	0.08	-
Total cost per child enrolled (USD, 2020) - hospitalization cost 200%	145.52	146.07	0.55	0.96	6.12
Total cost per child enrolled (USD, 2020) - supply chain cost same (C = 2*T)	130.89	122.62	-8.28	0.20	-
Effectiveness (success rate)	0.63	0.72	0.09	0.00	

ACCEPTED MANUSCRIPT